The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

The present invention is directed to an oral pharmaceutical dosage form comprising a capsule containing at least two tablets, each tablet containing at least one different pharmaceutically active ingredient

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C.sub.max, AUC.sub.0-t and/or AUC.sub.0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Disclosed are an oral solid dosage form composition comprising an active ingredient and a solubilizing carrier wherein a foaming ingredient is used to improve disintegration, dispersion or dissolution, and a preparation method therefor.

A liquisolid tablet formulation, comprising a microcrystalline cellulose carrier; a silica coating; a crosslinked polyvinylpyrrolidone (PVP) superdisintegrant; a solvent comprising polyethylene glycol (PEG) 200 and caprylocaproyl macrogol-8 glycerides; tadalafil; and dapoxetine, wherein the liquid load factor of the formulation is 0.2-0.4 is provided. Methods of making the liquisolid tablet and methods of using the formulation for the treatment of male sexual dysfunction are also provided.

The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1

##STR00001##

wherein R.sup.1 is H, C.sub.1-6-alkyl, C.sub.0-4-alkyl-C.sub.3-6-cycloalkyl, C.sub.1-6-haloalkyl; R.sup.2 is H, C.sub.1-6-alkyl; X is an anion selected from the group consisting of chloride or dibenzoyltartrate; j is 1 or 2; and
processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor.

The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Disclosed herein Eire pharmaceutical compositions having a mixture of at least one active agent, an ion exchange resin, a binder, and a matrix material such that the composition, when administered to a patient in need thereof, provides the patient with a therapeutic effect for at least about 8 hours and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

Rapid onset and extended action plant-based medicinal compounds or nutritional supplements and synthetic cannabinoid formulations are described. Rapid onset is provided by N-acylated fatty amino acids and/or penetration enhancers. Extended action can be provided by one or more sustained-release systems.